Trials / Not Yet Recruiting
Not Yet RecruitingNCT06551896
Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor
Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor: a Single Arm, Multiple Center, Phase II Study (Pigeon Study)
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This prospective phase Il study is aim to evaluate the efficacy and safety of FGFR inhibitor combined with immune checkpoint inhibitors in FGFR1/2/3 variant advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pemigatinib | Pemigatinib and immune checkpoint inhibitors |
Timeline
- Start date
- 2024-08-15
- Primary completion
- 2026-07-31
- Completion
- 2026-12-31
- First posted
- 2024-08-13
- Last updated
- 2024-08-13
Source: ClinicalTrials.gov record NCT06551896. Inclusion in this directory is not an endorsement.